So much of our work at the FDA continually revolves around the concept of “access” to needed medical therapies. Among many other areas, access is central to our efforts toward increasing availability of potentially cost-saving generic drugs and biosimilars for the American public, assuring quality manufacturing to avoid drug shortages, and helping patients with no option to use